المؤلفون: Creemers, Jeroen H A, Pawlitzky, Inka, Grosios, Konstantina, Gileadi, Uzi, Middleton, Mark R, Gerritsen, Winald R, Mehra, Niven, Rivoltini, Licia, Walters, Ian, Figdor, Carl G, Ottevanger, Petronella B, de Vries, I Jolanda M

المساهمون: European Union

المصدر: BMJ Open ; volume 11, issue 11, page e050725 ; ISSN 2044-6055 2044-6055

الإتاحة: https://doi.org/10.1136/bmjopen-2021-050725Test

المؤلفون: Coupe, Nicholas, Guo, Lina, Bridges, Esther, Campo, Leticia, Espinosa, Olivia, Colling, Richard, Marshall, Andrea, Nandakumar, Ashwin, van Stiphout, Ruud, Buffa, Francesca M., Corrie, Pippa G., Middleton, Mark R., Macaulay Valentine M.

المساهمون: Coupe, Nichola, Guo, Lina, Bridges, Esther, Campo, Leticia, Espinosa, Olivia, Colling, Richard, Marshall, Andrea, Nandakumar, Ashwin, van Stiphout, Ruud, Buffa, Francesca M., Corrie, Pippa G., Middleton, Mark R., Macaulay Valentine, M.

مصطلحات موضوعية: BRAF, MELANOMA, ROR2, WNT5A

وصف الملف: PRINT + ONLINE

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000901627300001; volume:46; issue:2; firstpage:391; lastpage:407; journal:CELLULAR ONCOLOGY; https://hdl.handle.net/11565/4061234Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85144344058; https://link.springer.com/article/10.1007/s13402-022-00757-7Test

الإتاحة: https://doi.org/10.1007/s13402-022-00757-7Test
https://hdl.handle.net/11565/4061234Test

المؤلفون: Solé, Carla, Tramonti, Daniela, Schramm, Maike, Goicoechea, Ibai, Armesto, Maria, Hernandez, Luiza I., Manterola, Lorea, Fernandez-Mercado, Marta, Mujika, Karmele, Tuneu, Anna, Jaka, Ane, Tellaetxe, Maitena, Friedländer, Marc R., Estivill, Xavier, Piazza, Paolo, Ortiz-Romero, Pablo L., Middleton, Mark R., Lawrie, Charles H.

المصدر: Cancers. 11(1)

مصطلحات موضوعية: melanoma, plasma, liquid biopsy, miRNA, mRNA, biomarker, YRNA, RNA species

وصف الملف: print

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-166630Test
https://doi.org/10.3390/cancers11010070Test

المؤلفون: Garbe, Claus, Amaral, Teresa M.S., Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Bastholt, Lars, Bataille, Véronique, del Marmol, Véronique, Dréno, Brigitte, Fargnoli, Maria Concetta, Grob, Jean Jacques, Höller, Christoph, Kaufmann, Roland, Lallas, Aimilios, Lebbé, Célèste, Malvehy, Josep, Middleton, Mark R., Moreno-Ramirez, David, Pellacani, Giovanni, Saiag, Phillippe, Stratigos, Alexander John, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M.M.

المساهمون: Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Aix-Marseille Université - Faculté des sciences médicales et paramédicales (AMU SMPM), Aix Marseille Université (AMU), Service de Dermatologie AP-HP Hôpital Saint-Louis, Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré AP-HP, Novartis Les Laboratories Pierre Fabre Berlin Mathematical School, BMS AbbVie Sanofi Pfizer Amgen Eisai GlaxoSmithKline, GSK Roche DUSA Pharmaceuticals Merck KGaA Meso Scale Diagnostics, MSD, C.G. reports receiving personal fees from Amgen, Pierre Fabre, Philogen and MSD, and reports receiving grants and personal fees from Novartis, NeraCare, BMS, Roche and Sanofi, outside the submitted work.T.A. reports receiving personal fees and other grants from BMS, Novartis, Pierre Fabre, Neracare and Sanofi, outside the submitted work.K.P. reports receiving personal fees from Novartis, Roche, Sanofi, Lilly, Leopharma, Pierre Fabre, Almirall and Celgene, outside the submitted work.A.H. reports receiving grants and personal fees from Amgen, BMS, MerckSerono, MSD / Merck, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, Sanofi-Genzyme, and Novartis Pharma, receiving personal fees from OncoSec and Sun Pharma, outside the submitted work.P.A. reports receiving personal fees from Amgen, MSD, Novartis, BMS and Roche, outside the submitted work.L.B. reports receiving grants from BMS, during the conduct of the study, personal fees from BMS, Novartis, Merck MSD, Roche, Incyte, Bayer, outside the submitted work.V.B. reports receiving personal fees from Novartis and Merck MSD, outside the submitted work.V.d.M. reports receiving personal fees from MSD, BMS and Sanofi, grants and personal fees from ABVIE, grants from Jansen, outside the submitted work.B.M. reports grants and personal fees from BMS, Roche, Fabre and Sanofi, personal fees from MSD, outside the submitted work.M.C.F. reports receiving grants and personal fees from Almirall, Leo Pharma, Novartis, Sanofi, Abbvie and Galderma, personal fees from Janssen, Lilly, UCB, Celgene, Pierre Fabre, Mylan, Medac Pharma, Roche, Sun Pharma, outside the submitted work.J.J.G. reports receiving personal fees from Amgen, MSD, Novartis, BMS, Roche, Pierre fabre, MercK / Pfizer, outside the submitted work.C.H. reports receiving personal fees from Amgen, MSD, Novartis, Incyte, BMS, Pierre Fabre, Roche, Sanofi, outside the submitted work.R.K. reports receiving grants and personal fees from Novartis and Roche, and grants from AbbVie, Amgen, Bionteck, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Pierre Fabre, Regeneron and Wyeth, outside the submitted work.A.L. reports personal fees from Amgen, Novartis, BMS and, Sanofi grants and personal fees from Roche, outside the submitted work.C.L. reports receiving grants and personal fees from Bristol-Myers Squibb and Roche, personal fees from MSD, Novartis, Amgen, Avantis Medical Systems, Pierre Fabre, Pfizer, Incyte, outside the submitted work.J.M. reports personal fees from Amgen, personal fees from MSD, grants from Novartis, grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from Almirall, personal fees from Sun Pharma, outside the submitted work.M.M. reports receiving personal fees from Amgen and BiolineRx, grants and personal fees from Roche and GSK, grants from Astrazeneca, personal fees and other from Novartis, Eisai, Array Biopharma (now Pfizer), Rigontec (acquired by MSD), and BMS, other from Millennium, Regeneron Pfizer, personal fees, non-financial support and other from Immunocore, Replimun and Merck / MSD, outside the submitted work.G.P. reports receiving personal fees from Novartis, personal fees from Sanofi, grants from Novartis, instruments from 3Gen, Vidix, Fotofinder and MAVIG GmbH, outside the submitted work.P.S. reports receiving personal fees from Amgen, MSD and Pierre Fabre / array, grants and personal fees from Novartis, NeraCare, BMS, Roche, and Sanofi, outside the submitted work.A.J.S. reports personal fees and/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr. Vieira has nothing to disclose.I.Z. reports receiving personal fees from Difa Cooper, MSD, Sanofi, Almirall Hermal, Novartis, Mylan and Sunpharma, grants and personal fees from Roche, outside the submitted work.A.M.M.E. reports receiving personal fees from Biocad, Biovent, BMS, CatalYm, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, Merck GmbH, MSD, Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SkylineDx, Stellas, other from RiverD, SkylineDx, Theranovir, all outside the submitted work.

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-03228160Test ; European Journal of Cancer, 2020, 126, pp.159-177. ⟨10.1016/j.ejca.2019.11.015⟩.

مصطلحات موضوعية: Adjuvant treatment, Cutaneous melanoma, Excisional margins, Interferon-α, Metastasectomy, Sentinel lymph node dissection, Systemic treatment, Tumour thickness, [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31866016; hal-03228160; https://hal.science/hal-03228160Test; https://hal.science/hal-03228160/documentTest; https://hal.science/hal-03228160/file/PIIS0959804919308342-1.pdfTest; PUBMED: 31866016

الإتاحة: https://doi.org/10.1016/j.ejca.2019.11.015Test
https://hal.science/hal-03228160Test
https://hal.science/hal-03228160/documentTest
https://hal.science/hal-03228160/file/PIIS0959804919308342-1.pdfTest

المؤلفون: Stratigos, Alexander J, Garbe, Claus, Dessinioti, Clio, Lebbe, Celeste, Bataille, Veronique, Bastholt, Lars, Dreno, Brigitte, Fargnoli, Maria Concetta, Forsea, Ana Maria, Frenard, Cecille, Harwood, Catherine Α, Hauschild, Axel, Hoeller, Christoph, Kandolf-Sekulovic, Lidija, Kaufmann, R, Kelleners-Smeets, Nicole Wj, Malvehy, Josep, Del Marmol, Veronique, Middleton, Mark R, Moreno-Ramirez, David, Pellecani, Giovanni, Peris, Ketty, Saiag, Philippe, van den Beuken-van Everdingen, Marieke H J, Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M M, Grob, Jean-Jacques, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)

مصطلحات موضوعية: Diagnosis, High-risk common primary cSCC, Imaging, Invasive cutaneous squamous cell carcinoma, Locally advanced Cscc, Low-risk, Metastatic cSCC, Prevention, Prognosis, Staging, Carcinoma, Squamous Cell, Consensus, Dermatology, Humans, Lymph Nodes, Magnetic Resonance Imaging, Medical Oncology, Neoplasm Staging, Patient Education as Topic, Positron Emission Tomography Computed Tomography, Protective Clothing, Risk Assessment, Skin, Skin Neoplasms, Societies, Medical, Sunlight, Sunscreening Agents, Ultrasonography

العلاقة: http://hdl.handle.net/10668/15183Test; https://arts.units.it/bitstream/11368/2966368/4/11368_2966368_print.pdfTest

الإتاحة: https://doi.org/10.1016/j.ejca.2020.01.007Test
http://hdl.handle.net/10668/15183Test
https://arts.units.it/bitstream/11368/2966368/4/11368_2966368_print.pdfTest

المؤلفون: Thomas, Anne, Virdee, Pradeep S., Eatock, Martin, Lord, Simon R., Falk, Stephen, Anthoney, D. Alan, Turkington, Richard C., Goff, Matthew, Elhussein, Leena, Collins, Linda, Love, Sharon, Moschandreas, Joanna, Middleton, Mark R.

المصدر: Thomas , A , Virdee , P S , Eatock , M , Lord , S R , Falk , S , Anthoney , D A , Turkington , R C , Goff , M , Elhussein , L , Collins , L , Love , S , Moschandreas , J & Middleton , M R 2020 , ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ' , European Journal of Cancer , ....

مصطلحات موضوعية: AZD8931, Dual erbB inhibitor, Oesophagogastric cancer, /dk/atira/pure/subjectarea/asjc/2700/2730, name=Oncology, /dk/atira/pure/subjectarea/asjc/1300/1306, name=Cancer Research, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being

وصف الملف: application/pdf

العلاقة: https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897Test

الإتاحة: https://doi.org/10.1016/j.ejca.2019.10.010Test
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897Test
https://pureadmin.qub.ac.uk/ws/files/197511651/1_s2.0_S0959804919307737_main.pdfTest

المؤلفون: Middleton, Mark R., Hoeller, Christoph, Michielin, Olivier, Robert, Caroline, Caramella, Caroline, Öhrling, Katarina, Hauschild, Axel

المساهمون: Medical writing support was funded by Amgen (Europe) GmbH.

المصدر: British Journal of Cancer ; volume 123, issue 6, page 885-897 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-020-0994-4Test
https://www.nature.com/articles/s41416-020-0994-4.pdfTest
https://www.nature.com/articles/s41416-020-0994-4Test

المؤلفون: Hemstock, Matthew, Amadi, Adenike, Kupas, Katrin, Roskell, Neil, Kotapati, Srividya, Gooden, Kyna, Middleton, Mark R., Schadendorf, Dirk

المساهمون: Bristol-Myers Squibb

المصدر: European Journal of Cancer ; volume 132, page 176-186 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.ejca.2020.03.011Test
https://api.elsevier.com/content/article/PII:S0959804920301520?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0959804920301520?httpAccept=text/plainTest

المؤلفون: Cheung, Vincent T., Gupta, Tarun, Olsson-Brown, Anna C., Subramanian, Sreedhar, Sasson, Sarah C., Heseltine, Jonathan, Fryer, Eve, Collantes-Bellido, Elena, Sacco, Joseph J., Pirmohamed, Munir, Simmons, Alison, Klenerman, Paul, Fairfax, Benjamin P., Payne, Miranda J., Middleton, Mark R., Brain, Oliver

المصدر: Gastroenterology ; volume 158, issue 6, page S-535-S-536 ; ISSN 0016-5085

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/s0016-5085Test(20)32033-3
https://api.elsevier.com/content/article/PII:S0016508520320333?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0016508520320333?httpAccept=text/plainTest

المؤلفون: Bannoud, Nadia, Stupirski, Juan C., Cagnoni, Alejandro J., Hockl, Pablo F., Pérez Sáez, Juan M., García, P. Alfredo, Mahmoud, Yamil D., Gambarte Tudela, Julián, Scheidegger, Marco A., Marshall, Andrea, Corrie, Pippa G., Middleton, Mark R., Mariño, Karina V., Girotti, M. Romina, Croci, Diego O., Rabinovich, Gabriel A.

مصطلحات موضوعية: QD Chemistry, QP Physiology, RB Pathology, RC Internal medicine

وصف الملف: application/pdf

العلاقة: https://wrap.warwick.ac.uk/172747/1/WRAP-Circulating-galectin-1-delineates-response-to-bevacizumab-in-melanoma-patients-and-reprograms-endothelial-cell-biology-Marshall-2023.pdfTest; Bannoud, Nadia, Stupirski, Juan C., Cagnoni, Alejandro J., Hockl, Pablo F., Pérez Sáez, Juan M., García, P. Alfredo, Mahmoud, Yamil D., Gambarte Tudela, Julián, Scheidegger, Marco A., Marshall, Andrea, Corrie, Pippa G., Middleton, Mark R., Mariño, Karina V., Girotti, M. Romina, Croci, Diego O. and Rabinovich, Gabriel A. (2023) Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology. Proceedings of the National Academy of Sciences of the United States of America, 120 (3). e2214350120. doi:10.1073/pnas.2214350120 ISSN 0027-8424.

الإتاحة: https://doi.org/10.1073/pnas.2214350120Test
https://wrap.warwick.ac.uk/172747Test/
https://wrap.warwick.ac.uk/172747/1/WRAP-Circulating-galectin-1-delineates-response-to-bevacizumab-in-melanoma-patients-and-reprograms-endothelial-cell-biology-Marshall-2023.pdfTest